The best treatment is sometimes none at all

DePaolis, Michael D.
September 2008
Primary Care Optometry News;Sep2008, Vol. 13 Issue 9, p3
The author asserts the need for optometrists to consider quality of life before proceeding with therapeutics or surgery. He cites the implementation of quality of life metrics for assessing the efficacy of certain new drugs and devices by the U.S. Food and Drug Administration (FDA). He describes the case of a patient with multiple eye diseases whose best treatment was no treatment at all. He notes that the family of the patient opted for no treatment due to concern about the patient's comfort.


Related Articles

  • Paroxetine Capsules (Brisdelleâ„¢). Elliott, William T.; Chan, James // Internal Medicine Alert;7/29/2013, Vol. 35 Issue 14, p110 

    The article focuses on a study that was conducted to examine the efficacy and safety of paroxetine for the treatment of vasomotor symptoms in postmenopausal women.

  • TIPPING POINTS: Topography-Guided Treatments and the Optometrist.  // Optometry Times;Dec2015 Supplement Tipping points, p2 

    The article reports on the U.S. Food and Drug Administration's approval of WaveLight® Allegretto Wawe® Eye-Q Excimer Laser system, a topography-guided refractive treatment system.

  • Update on Ra-223 Therapy after FDA Approval. Mittra, Erik // AUANews;Apr2015, Vol. 20 Issue 4, p16 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) in April 2015 of the application of alpha-emitting targeted radioisotope radium-223 dichloride Xofigo therapy in patients with metastatic castration resistant prostate cancer. Its overall survival, quality of life...

  • Management of Patients with Advanced Non-Small Cell Lung Cancer. Triano, Laura R.; Deshpande, Hari; Gettinger, Scott N. // Drugs;2010, Vol. 70 Issue 2, p167 

    Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly...

  • Long-awaited insulin inhaler approved. Belden, Heidi // Drug Topics;3/6/2006, Vol. 150 Issue 5, p17 

    The article reports on the approval given to Exubera Inhalation Powder from Pfizer Inc. by the U.S. Food and Drug Administration (FDA) for the treatment of adults with type 1 and type 2 diabetes. According to the director of FDA Center for Drug Evaluation & Research Steven Galson , the...

  • Discovery Pipeline. Ritter, Amy // BioPharm International;Apr2012, Vol. 25 Issue 4, p12 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the first allogenic cell-based therapy, called GINTUIT, which uses cells unrelated to the patient to create the therapeutic.

  • FDA research uncovers clues on serious diseases.  // FDA Consumer;Mar/Apr98, Vol. 32 Issue 2, p4 

    Presents the results of two studies that may change the way some life-threatening illnesses are treated published by US Food and Drug Administration. Name of the publications in which the results of the study have been published; Medical conditions in which this discovery may have potential...

  • Unapproved But Not Always Unavailable. Thompson, Larry // FDA Consumer;Jan/Feb2000, Vol. 34 Issue 1, p8 

    Discusses the issue of the availability of experimental treatments for seriously ill patients in the United States. Percent of drugs in testing that will ultimately be approved; Incorrect perception of the public about the Food and Drug Administration; Pros and cons of experimental treatments;...

  • Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents. Childress, Ann C.; Berry, Sally A. // Drugs;2012, Vol. 72 Issue 3, p309 

    Attention-deficit hyperactivity disorder (ADHD) is a common neuro-behavioural disorder in children and adolescents, consisting of developmentally inappropriate levels of inattention and/or hyperactivity and impulsivity. The majority of children with ADHD will continue to experience significant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics